Significant association between IL23R and IL17F polymorphisms and clinical features of colorectal cancer

Immunology Letters

Volumn 158, Issue 1-2, 2014, Pages 189-194

  Omrane, Inés ^a   Baroudi, Olfa ^a   Bougatef, Karim ^a   Mezlini, Amel ^b   Abidi, Ahmed ^a   Medimegh, Imen ^a   Stambouli, Nejla ^a   Ayari, Hager ^a   Kourda, Nadia ^c   Uhrhammer, Nancy ^d   Bignon, Yves Jean ^d   Benammar Elgaaied, Amel ^a   Marrakchi, Raja ^a  

^a UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

^b SALAH AZAIEZ INSTITUTE   (Tunisia)

^c CHARLES NICOLLE HOSPITAL   (Tunisia)

^d CENTRE JEAN PERRIN   (France)

Author keywords

Clinical features; Colorectal cancer; IL17 IL23R; Immunity; Polymorphism; Th17 cells

Indexed keywords

AUTACOID; IL23R PROTEIN, HUMAN; INTERLEUKIN 17; INTERLEUKIN RECEPTOR;

AGED; CANCER STAGING; CARCINOGENESIS; CARCINOMA; COLORECTAL TUMOR; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOLOGY; MALE; METABOLISM; METASTASIS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUNISIA;

AGED; CARCINOGENESIS; CARCINOMA; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-17; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POLYMORPHISM, GENETIC; RECEPTORS, INTERLEUKIN; TUNISIA;

EID: 84893656308     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.01.002     Document Type: Article

References (63)

1. McGovern D.P., Rotter J.I., Mei L., Haritunians T., Landers C., Derkowski C., et al. Genetic epistasis of IL23/IL17 pathway genes in Crohn's disease. Inflamm Bowel Dis 2009, 15:883-889.
2. Yamada H. Current perspectives on the role of IL-17 in autoimmune disease. Journal of inflammation research;3:33-44.
3. Clevers H. At the crossroads of inflammation and cancer. Cell 2004, 118:671-674.
4. Sakamoto K., Maeda S., Hikiba Y., Nakagawa H., Hayakawa Y., Shibata W., et al. Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res 2009, 15:2248-2258.
5. Wang S., Liu Z., Wang L., Zhang X. NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol 2009, 6:327-334.
6. Macarthur M., Hold G.L., El-Omar E.M. Inflammation and cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol 2004, 286:G515-520.
7. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007, 117:1175-1183.
8. Atreya I., Atreya R., Neurath M.F. NF-kappaB in inflammatory bowel disease. J Intern Med 2008, 263:591-596.
9. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev 2005, 5:749-759.
10. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
11. Cacev T., Jokic M., Loncar B., Krizanac S., Kapitanovic S. Interleukin-6-174 G/C polymorphism is not associated with IL-6 expression and susceptibility to sporadic colon cancer. DNA Cell Biol 2010, 29:177-182.
12. Cacev T., Radosevic S., Krizanac S., Kapitanovic S. Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis 2008, 29:1572-1580.
13. de Jong M.M., Nolte I.M., te Meerman G.J., van der Graaf W.T., de Vries E.G., Sijmons R.H., et al. Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev 2002, 11:1332-1352.
14. Ito H., Kaneko K., Makino R., Konishi K., Kurahashi T., Yamamoto T., et al. Interleukin-1beta gene in esophageal, gastric and colorectal carcinomas. Oncol Rep 2007, 18:473-481.
15. Landi S., Moreno V., Gioia-Patricola L., Guino E., Navarro M., de Oca J., et al. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 2003, 63:3560-3566.
16. Spaska Stanilova Colorectal Cancer Biology-From Genes to Tumor; 2012.
17. Baier P.K., Wolff-Vorbeck G., Eggstein S., Baumgartner U., Hopt U.T. Cytokine expression in colon carcinoma. Anticancer Res 2005, 25:2135-2139.
18. Le Gouvello S., Bastuji-Garin S., Aloulou N., Mansour H., Chaumette M.T., Berrehar F., et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008, 57:772-779.
19. Terzic J., Grivennikov S., Karin E., Karin M. Inflammation and colon cancer. Gastroenterology 2010, 138:2101-2114 e2105.
20. Ma C., Dong X. Colorectal cancer-derived Foxp3(+) IL-17(+) T cells suppress tumour-specific CD8+ T cells. Scand J Immunol 2011, 74:47-51.
21. Tosolini M., Kirilovsky A., Mlecnik B., Fredriksen T., Mauger S., Bindea G., et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011, 71:1263-1271.
22. Kawaguchi M., Adachi M., Oda N., Kokubu F., Huang S.K. IL-17 cytokine family. J Allergy Clin Immunol 2004, 114:1265-1273. quiz 1274.
23. Kolls J.K., Linden A. Interleukin-17 family members and inflammation. Immunity 2004, 21:467-476.
24. Ishigame H., Kakuta S., Nagai T., Kadoki M., Nambu A., Komiyama Y., et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009, 30:108-119.
25. Nordang G.B., Viken M.K., Hollis-Moffatt J.E., Merriman T.R., Forre O.T., Helgetveit K., et al. Association analysis of the interleukin 17A gene in Caucasian rheumatoid arthritis patients from Norway and New Zealand. Rheumatology (Oxford, England) 2009, 48:367-370.
26. Arisawa T., Tahara T., Shibata T., Nagasaka M., Nakamura M., Kamiya Y., et al. The influence of polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to ulcerative colitis. J Clin Immunol 2008, 28:44-49.
27. Shibata T., Tahara T., Hirata I., Arisawa T. Genetic polymorphism of interleukin-17A and -17F genes in gastric carcinogenesis. Hum Immunol 2009, 70:547-551.
28. Wu X., Zeng Z., Chen B., Yu J., Xue L., Hao Y., et al. Association between polymorphisms in interleukin-17A and interleukin-17F genes and risks of gastric cancer. Int J Cancer 2010, 127:86-92.
29. Tahara T., Shibata T., Nakamura M., Yamashita H., Yoshioka D., Okubo M., et al. Effect of polymorphisms of IL-17A, -17F and MIF genes on CpG island hyper-methylation (CIHM) in the human gastric mucosa. Int J Mol Med 2009, 24:563-569.
30. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198:1951-1957.
31. Abraham C., Cho J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis 2009, 15:1090-1100.
32. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
33. Huber A.K., Jacobson E.M., Jazdzewski K., Concepcion E.S., Tomer Y. Interleukin (IL)-23 receptor is a major susceptibility gene for Graves' ophthalmopathy: the IL-23/T-helper 17 axis extends to thyroid autoimmunity. J Clin Endocrinol Metab 2008, 93:1077-1081.
34. Dubinsky M.C., Wang D., Picornell Y., Wrobel I., Katzir L., Quiros A., et al. IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease. Inflamm Bowel Dis 2007, 13:511-515.
35. Capon F., Di Meglio P., Szaub J., Prescott N.J., Dunster C., Baumber L., et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007, 122:201-206.
36. Illes Z., Safrany E., Peterfalvi A., Magyari L., Farago B., Pozsonyi E., et al. 3'UTR C2370A allele of the IL-23 receptor gene is associated with relapsing-remitting multiple sclerosis. Neurosci Lett 2008, 431:36-38.
37. Bin C., Zhirong Z., Xiaoqin W., Minhu C., Mei L., Xiang G., et al. Contribution of rs11465788 in IL23R gene to Crohn's disease susceptibility and phenotype in Chinese population. J Genet 2009, 88:191-196.
38. Okazaki T., Wang M.H., Rawsthorne P., Sargent M., Datta L.W., Shugart Y.Y., et al. Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn's disease risk in a population-based case-control study: evidence of gene-gene interactions. Inflamm Bowel Dis 2008, 14:1528-1541.
39. Zhang Z., Zhou B., Zhang J., Chen Y., Lai T., Yan L., et al. Association of interleukin-23 receptor gene polymorphisms with risk of ovarian cancer. Cancer Genet Cytogenet 2010, 196:146-152.
40. Chien M.H., Hsin C.H., Chou L.S., Chung T.T., Lin C.H., Weng M.S., et al. Interleukin-23 receptor polymorphism as a risk factor for oral cancer susceptibility. Head Neck 2012, 34:551-556.
41. Lan F., Zhang L., Wu J., Zhang J., Zhang S., Li K., et al. IL-23/IL-23R: potential mediator of intestinal tumor progression from adenomatous polyps to colorectal carcinoma. Int J Colorectal Dis 2011, 26:1511-1518.
42. Suzuki H., Ogawa H., Miura K., Haneda S., Watanabe K., Ohnuma S., et al. IL-23 directly enhances the proliferative and invasive activities of colorectal carcinoma. Oncol Lett 2012, 4:199-204.
43. Poole E.M., Curtin K., Hsu L., Duggan D.J., Makar K.W., Xiao L., et al. Genetic variability in IL23R and risk of colorectal adenoma and colorectal cancer. Cancer Epidemiol 2012, 36:e104-e110.
44. Vasen H.F., van der Meulen-de Jong A.E., de Vos Tot Nederveen Cappel W.H., Oliveira J. Familial colorectal cancer risk: ESMO clinical recommendations. Ann Oncol 2009, 4(Suppl. 20):51-53.
45. Carter A.B., Misyak S.A., Hontecillas R., Bassaganya-Riera J. Dietary modulation of inflammation-induced colorectal cancer through PPARgamma. PPAR Res 2009, 498352.
46. Tanaka T. Development of an inflammation-associated colorectal cancer model and its application for research on carcinogenesis and chemoprevention. Internat J Inflam 2012, 658786.
47. Bernstein C.N., Blanchard J.F., Kliewer E., Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001, 91:854-862.
48. Lakatos P.L., Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 2008, 14:3937-3947.
49. Wilkening S., Tavelin B., Canzian F., Enquist K., Palmqvist R., Altieri A., et al. Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis 2008, 29:1202-1206.
50. Erdman S.E., Poutahidis T. Roles for inflammation and regulatory T cells in colon cancer. Toxicol Pathol 2010, 38:76-87.
51. Kryczek I., Wei S., Zou L., Altuwaijri S., Szeliga W., Kolls J., et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007, 178:6730-6733.
52. Liu J., Duan Y., Cheng X., Chen X., Xie W., Long H., et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 2011, 407:348-354.
53. Chu H., Cao W., Chen W., Pan S., Xiao Y., Liu Y., et al. Potentially functional polymorphisms in IL-23 receptor and risk of esophageal cancer in a Chinese population. Int J Cancer 2012, 130:1093-1097.
54. Wang L., Liu W., Jiang W., Lin J., Jiang Y., Li B., et al. A miRNA binding site single-nucleotide polymorphism in the 3'-UTR region of the IL23R gene is associated with breast cancer. PLoS One 2012, 7:e49823.
55. Zhou B., Zhang P., Wang Y., Shi S., Zhang K., Liao H., et al. Interleukin-17 gene polymorphisms are associated with bladder cancer in a chinese han population. Mol Carcinog 2013, 52:871-878.
56. Chen J., Deng Y., Zhao J., Luo Z., Peng W., Yang J., et al. The polymorphism of IL-17 G-152A was associated with childhood asthma and bacterial colonization of the hypopharynx in bronchiolitis. J Clin Immunol 2010, 30:539-545.
57. Yu P., Shen F., Zhang X., Cao R., Zhao X., Liu P., et al. Association of single nucleotide polymorphisms of IL23R and IL17 with ulcerative colitis risk in a Chinese Han population. PLoS One 2012, 7:e44380.
58. Luzza F., Parrello T., Monteleone G., Sebkova L., Romano M., Zarrilli R., et al. Up-regulation of IL-17 is associated with bioactive IL-8 expression in Helicobacter pylori-infected human gastric mucosa. J Immunol 2000, 165:5332-5337.
59. Mizuno T., Ando T., Nobata K., Tsuzuki T., Maeda O., Watanabe O., et al. Interleukin-17 levels in Helicobacter pylori-infected gastric mucosa and pathologic sequelae of colonization. World J Gastroenterol 2005, 11:6305-6311.
60. Tong Z., Yang X.O., Yan H., Liu W., Niu X., Shi Y., et al. A protective role by interleukin-17F in colon tumorigenesis. PLoS One 2012, 7:e34959.
61. Radosavljevic G., Ljujic B., Jovanovic I., Srzentic Z., Pavlovic S., Zdravkovic N., et al. Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma. Neoplasma 2010, 57:135-144.
62. Wagsater D., Lofgren S., Hugander A., Dimberg J. Expression of interleukin-17 in human colorectal cancer. Anticancer Res 2006, 26:4213-4216.
63. Zheng J., Jiang L., Zhang L., Yang L., Deng J., You Y., et al. Functional genetic variations in the IL-23 receptor gene are associated with risk of breast, lung and nasopharyngeal cancer in Chinese populations. Carcinogenesis 2012, 33:2409-2416.